# CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

> **NCT04639362** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland** · enrollment: 85 (actual)

## Conditions studied

- CLL

## Interventions

- **DRUG:** ibrutinib, venetoclax, obinutuzumab
- **DRUG:** ibrutinib, venetoclax

## Key facts

- **NCT ID:** NCT04639362
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-29
- **Primary completion:** 2025-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2021-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639362, "CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04639362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*